- Investigator
- Ginger Clark
- Status
- Accepting Candidates
Research at a glance
Top areas of exploration
- Liver Cirrhosis , 8 publications
- Hepatitis C , 8 publications
- alpha 1-Antitrypsin Deficiency , 6 publications
- Antiviral Agents , 6 publications
Research activity
Active clinical trials
The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-alpha-1 antitrypsin (Z-AAT) protein. People who have taken part in previous fazirsiran studies (AROAAT2001鈥�
- Investigator
- Ginger Clark
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body鈥�
- Investigator
- Ginger Clark
- Status
- Accepting Candidates
- Ages
- 18 Years - 75 Years
- Sexes
- All
My publications
Filter publications
42 publications
2024
Reply
Gastroenterology
2024
Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease.
Alimentary pharmacology & therapeutics
鈥�2022
Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency.
Gut
鈥�2021
Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study.
Journal of hepatology
鈥�2021
Quantitative measurement of the histological features of alpha-1 antitrypsin deficiency-associated liver disease in biopsy specimens.
PloS one
鈥�